Profile

Research

Publications

Team

Alumni

Devasena Anantharaman, PhD

Scientist E II

+91-471-2529590

devasena@rgcb.res.in

Devasena Anantharaman
Devasena Anantharaman

Devasena Anantharaman, PhD

Scientist E II

+91-471-2529590

devasena@rgcb.res.in

  • Profile

    • Ph.D Applied Biology (University of Mumbai)
    • M.Sc Environmental Toxicology (Madras University)
    • B.Sc Zoology & Biotechnology (University of Mumbai)
    • December 2016 – Till date, Scientist E-II Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala
    • April 2015- August 2016, Scientist, International Agency for Research on Cancer (IARC- WHO), Lyon, France
    • February 2013- February 2015, Scientist, International Agency for Research on Cancer (IARC-WHO), Lyon, France
    • January 2009- January 2013, Post-Doctoral Researcher, International Agency for Research on Cancer (IARC-WHO), Lyon, France
  • Research

    Research Summary

    Our lab investigates the contribution of HPV infections in several cancers with the aim of understanding cancer aetiology and contributing to primary and secondary prevention of cancer. These objectives are achieved throughcollaborative studies, which integrate large scale epidemiologic studies (with lifestyle and environmental exposure data) with high throughput methods (e.g. multiplex HPV testing methods, large-scale targeted gene sequencing, whole exome and RNA sequencing). An important thrust area of our research includes head and neck cancerswhere we focus on biomarker discovery for oral cancer risk prediction, estimating the proportion of HPV driven cancers at each anatomic subsite, unravelling whether this proportion varies by geographic location in the country, identifying accurate markers for classification and prognosis of HPV-related cancers and providing an insight into the natural history of oral HPV infections among cancer-free healthy individuals. Another important focus of our research is in the domain of cervical cancer prevention, particularly in demonstrating short term vaccine efficacy with respect to immunogenicity and infection rates following vaccination with the quadrivalent HPV vaccine. In this context, we are also interested in identifying immune correlates of long lasting highly specific B and T cell mediated immune memory response to HPV vaccination.Our lab also manages an advanced testing facility for human papillomavirus (HPV) research that includes multiplex HPV genotyping and serology assays using the high throughput Luminex platform.

    Research Programs - Human papillomavirus (HPV)-related oropharyngeal cancer incidence and trends in India

    Human papillomavirus (HPV) related cancers are sexually transmitted diseases. HPV is known to cause cervical,vulvar, anal, penile and a subset of oropharynx cancers. While the incidence rate of oropharynx cancer is increasing in the West, primarily due to the increasing the HPV-positive subset, the status of these cancers in India remains unclear. Globally, HPV prevalence in oropharynx cancervaries dramatically. Whether India, with diverse sociodemographic features, experiences similar variability is not known.Our research program will provide accurate estimates for the HPV-related OPC subset with respect to: incidence,trends (if any) and potential geographic variability across the nation. This is a major research program funded by the Wellcome Trust (UK) India Alliance program by the Department of Biotechnology (DBT).

    Research Programs - Understanding the natural history of oral HPV infection: an Indian perspective

    The recognition of HPV-related cancers in men has triggered the advocacy of male vaccination toprotect against HPV-related genital and oral cancer, particularly in settings of low vaccine uptake among women. It is clear that vaccination must precede infection in order to be effective. Prior to a meaningful discussion on cost-effectiveness of vaccinating boys or the reduction in potential cancer risk, it remains obvious that more evidence regarding the burden of infections is needed. Through a prospective population-based study, we will estimate oral HPV prevalence, incidence and clearance rates among healthy cancer-free men.This project will provide novel insights into the natural history of oral HPV infections and lead to a better understanding of natural immune responses to non-genital HPV infections in men. This is a major research program funded by the Wellcome Trust (UK) India Alliance program by the Department of Biotechnology (DBT).

    Research Programs - Biomarkers of oral cancer risk prediction

    Oral cancer is the most common malignancy in India for which oral potentially premalignant lesions serve as early indicators of damage. Although it has been recognized for decades that not all oral precancers progress to frank malignancies, no biomarkers exist that can identify patients with a high risk of progression. Further, the overall 5-year survival of oral cancer patients has only improved slightly over the past several decades. Treatment often requires aggressive, multimodality management that results in the loss of oro-facial function, pain, and disfigurement. At present, cancer treatment and prognosis is heavily dependent on stage. Yet, the ability of staging to predict prognosis is limited; patients with tumors of the same clinical and pathologic staging have heterogeneous response to clinical treatment, and different probability of recurrence and survival. Therefore we aim to identify and validate biomarkers of oral cancer risk prediction. This is a major research program funded by the Department of Biotechnology (DBT).

    Research Programs - Aetiology of human papillomavirus infections in head and neck cancer

    India reports the highest rate of cancers arising at the oral cavity, pharynx and larynx, grouped together as head and neck cancers. The high rate of occurrence has been attributed to the prevalence of tobacco chewing. In addition, smoking and alcohol consumption are also known to cause these cancers. Recently, human papillomavirus (HPV) infection, previously known to cause cervical, vulvar, anal and penile cancers, have been implicated in a subset particularly those arising at the oropharynx. My lab is interested in filling the existing knowledge gaps in this area by estimating the proportion of HPV driven cancers at each of these sites, identifying accurate markers for classification and prognosis of HPV-related cancers and elucidating the interactions between multiple risk factors in risk of this disease. We therefore work in research partnerships with teams comprising clinical oncologists, pathologists, biologists, and epidemiologists. All studies involving patients, tumor tissue and population studies are done through a network of collaborations with Institutes across the country.This research program is funded by the Indian Council of Medical Research (ICMR).

    Research Programs - Molecular HPV tests to establish endpoints for primary prevention of cervical cancer

    Bivalent and a quadrivalent HPV vaccines are currently available that can prevent infections with HPV types that cause upto 70% of cervical cancers. Since an increase in worldwide HPV vaccination, particularly in low-resource settings like India, could be facilitated if fewer than three doses of vaccine would be as effective as three doses, a multicentre, cluster-randomised trial was initiated in India. Using theadvanced human papillomavirus (HPV) testing facility in our lab, this existing program examines the short term vaccine efficacy in terms of immunogenicity and infection rates after vaccination. This program is funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC-WHO).

    Research Programs - Correlates of long lasting cell-mediated immune memory response to HPV vaccination

    An effective virus-like particle (VLP) based prophylactic vaccine will need to induce a strong humoral and cellular immune response capable of providing long-term protection. Long term immune memory is known to be mediated through a subset of plasma cells that persist as antigen-specific memory B and T cells. Our lab is interested in characterizing long lasting highly specific HPV L1 VLP memory B cells and T cell mediated response to HPV vaccination.

    1. 2019 - 2024 : Human papillomavirus (HPV)-related oropharyngeal cancer burdenand the natural history of oral HPV infections: an Indianperspective.
      Wellcome Trust (UK) India Alliance program by the Department of Biotechnology (DBT)
    2. 2018 - 2021 :Biomarkers of oral cancer risk prediction
      Department of Biotechnology (DBT)
  • Publications

    1. Predictors of oropharyngeal cancer survival in Europe. D. Anantharaman, A. Billot, T. Waterboer, T. Gheit, B. Abedi-Ardekani, P. Lagiou, A. Lagiou, W. Ahrens, I. Holcátová, F. Merletti, K. Kjaerheim, J. Polesel, L. Simonato, L. Alemany, M. Mena Cervigon, T.V. Macfarlane, A. Znaor, P.J. Thomson, M. Robinson, C. Canova, D.I. Conway, S. Wright, C.M. Healy, M.E. Toner, M. Pawlita, M. Tommasino, P. Brennan. Oral Oncology 2018, 81, 89-94. doi: 10.1016/j.oraloncology.2018.04.016
    2. The influence of smoking, age and stage at diagnosis on the survival after larynx, hypopharynx and oral cavity cancers in Europe: The ARCAGE study. Abrahão R, Anantharaman D, Gaborieau V, Abedi-Ardekani B, Lagiou P, Lagiou A, Ahrens W, Holcatova I, Betka J, Merletti F, Richiardi L, Kjaerheim K, Serraino D, Polesel J, Simonato L, Alemany L, AgudoTrigueros A, Macfarlane TV, Macfarlane GJ, Znaor A, Robinson M, Canova C, Conway DI, Wright S, Healy CM, Toner M, Cadoni G, Boccia S, Gheit T, Tommasino M, Scelo G, Brennan P. International Journal of Cancer. 2018 Jul 1;143(1):32-44. doi: 10.1002/ijc.31294.PMID: 29405297
    3. Comparative Analysis of New Staging Systems for HPV-associated Oropharyngeal Squamous Cell Carcinoma in a Population-Based Cohort. AM Tanner, A Mazul, D Farquhar, J Taylor, P Brennan, D Anantharaman, B Abedi-Ardekani, NN Hayes, M Weissler, S Patel, BS Chera, AOlshan, JP Zevallos. International Journal of Radiation Oncology Biology Physics 2018 100 (5), 1350
    4. Genomic analysis of head and neck cancer cases from two high incidence regions. Perdomo S, Anantharaman D, Foll M, Abedi-Ardekani B, Durand G, Reis Rosa LA, Holmila R, Le Calvez-Kelm F, Tajara EH, Wünsch-Filho V, Levi JE, Vilensky M, Polesel J, Holcatova I, Simonato L, Canova C, Lagiou P, McKay JD, Brennan P. PLoS One. 2018 Jan 29;13(1):e0191701. doi: 10.1371/journal.pone.0191701. PMID: 29377909
    5. Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches. Perdomo S, Avogbe PH, Foll M, Abedi-Ardekani B, Facciolla VL, Anantharaman D, Chopard P, Calvez-Kelm FL, Vilensky M, Polesel J, Holcatova I, Simonato L, Canova C, Lagiou P, McKay JD, Brennan P. Oncotarget. 2017 Aug 7;8(42):72621-72632. doi: 10.18632/oncotarget.20004. PMID: 29069814
    6. Development and validation of a protocol for optimizing the use of paraffin blocks in molecular epidemiological studies: The example from the HPV-AHEAD study. Mena M, Lloveras B, Tous S, Bogers J, Maffini F, Gangane N, Kumar RV, Somanathan T, Lucas E, Anantharaman D, Gheit T, Castellsagué X, Pawlita M, de Sanjosé S, Alemany L, Tommasino M; HPV-AHEAD study group. PLoS One. 2017 Oct 16;12(10):e0184520. doi: 10.1371/journal.pone.0184520. PMID: 29036167
    7. Role of mucosal high-risk human papillomavirus types in head and neck cancers in central India. Gheit T, Anantharaman D, Holzinger D, Alemany L, Tous S, Lucas E, Prabhu PR, Pawlita M, Ridder R, Rehm S, Bogers J, Maffini F, Chiocca S, Lloveras B, Kumar RV, Somanathan T, de Sanjosé S, Castellsagué X, Arbyn M, Brennan P, Sankaranarayanan R, Pillai MR, Gangane N, Tommasino M; HPV-AHEAD study group. International Journal of Cancer. 2017 Jul 1;141(1):143-151. doi: 10.1002/ijc.30712. PMID: 28369859
    8. Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer.Anantharaman D, Abedi-Ardekani B, Beachler DC, Gheit T, Olshan AF, Wisniewski K, Wunsch-Filho V, Toporcov TN, Tajara EH, Levi JE, Moyses RA, Boccia S, Cadoni G, Rindi G, Ahrens W, Merletti F, Conway DI, Wright S, Carreira C, Renard H, Chopard P, McKay-Chopin S, Scelo G, Tommasino M, Brennan P*, D'Souza G. International Journal of Cancer. 2017 Jan 20. doi: 10.1002/ijc.30608. PMID: 28108990
    9. Oral health and human papillomavirus-associated head and neck squamous cell carcinoma.Mazul AL, Taylor JM, Divaris K, Weissler MC, Brennan P, Anantharaman D, Abedi-Ardekani B, Olshan AF, Zevallos JP*. Cancer. 2017 Jan 1;123(1):71-80. doi: 10.1002/cncr.30312. PMID: 27571516
    10. Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents.D'Souza G, Anantharaman D, Gheit T, Abedi-Ardekani B, Beachler DC, Conway DI, Olshan AF, Wunsch-Filho V, Toporcov TN, Ahrens W, Wisniewski K, Merletti F, Boccia S, Tajara EH, Zevallos JP, Levi JE, Weissler MC, Wright S, Scelo G, Mazul AL, Tommasino M, Brennan P*, Cadoni G. Oral Oncology. 2016 Nov;62:20-27. doi: 10.1016/j.oraloncology.2016.09.005. PMID: 27865368 (*Joint first author publication)
    11. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, Menezes AM, Curado MP, Robinson M, Ahrens W, Canova C, Znaor A, Castellsagué X, Conway DI, Holcátová I, Mates D, Vilensky M, Healy CM, Szeszenia-Dabrowska N, Fabiánová E, Lissowska J, Grandis JR, Weissler MC, Tajara EH, Nunes FD, de Carvalho MB, Thomas S, Hung RJ, Peters WH, Herrero R, Cadoni G, Bueno-de-Mesquita HB, Steffen A, Agudo A, Shangina O, Xiao X, Gaborieau V, Chabrier A, Anantharaman D, Boffetta P, Amos CI, McKay JD, Brennan P*. Nature Genetics. 2016 Dec;48(12):1544-1550. doi: 10.1038/ng.3685. PMID: 27749845
    12. Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma.Mazul AL, Rodriguez-Ormaza N, Taylor JM, Desai DD, Brennan P, Anantharaman D, Gheit T, Tommasino M, Abedi-Ardekani B, Olshan AF, Zevallos JP*. Oral Oncology. 2016 Oct;61:98-103. doi: 10.1016/j.oraloncology.2016.08.019. PMID: 27688111
    13. Combined effects of smoking & HPV16 in oropharyngeal cancer. Anantharaman D, Muller DC, Lagiou P, Ahrens W, Holcátová I, Merletti F, Kjaerheim K, Polesel J, SimonatoL,CanovaC,CastellsagueX,Macfarlane TV, Znaor A, Thomson P,RobinsonM,Conway DI, Healy CM, Tjønneland A, Westin U, Ekström J, Chang-Claude J, Kaaks R, Overvad K, Drogan D, Hallmans G, Laurell G, Bueno-de-Mesquita H.B(as)., Peeters PH, Agudo A, Larrañaga N, Travis RC, Palli D, Barricarte A, Trichopoulou A, George S, Trichopoulos D, Quirós JR, Grioni S, Sacerdote C, Navarro C, Sánchez MJ, Tumino R, Severi G, Boutron-Ruault MC, Clavel F, Panico S, Weiderpass E, Lund E, Gram IT, Riboli E, Pawlita M, Waterboer T, Kreimer AR, Johansson M, Brennan P*. International Journal of Epidemiology2016 Jun;45(3):752-61. PMID: 27197530
    14. Previous tonsillectomy modifies odds of tonsil and base of tongue cancer.Zevallos JP, Mazul AL, Rodriguez N, Weissler MC, Brennan P,Anantharaman D, Abedi-Ardekani B, Neil Hayes D, Olshan AF*. British Journal of Cancer. 2016 Mar 29; 114(7):832-8. doi: 10.1038/bjc.2016.63. PMID: 26977858
    15. Molecular Profile of Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma Stratified by Smoking Status. JP Zevallos*, E Yim, P Brennan, AY Liu, JM Taylor, M Weissler, D Anantharaman, B Abedi-Ardekani, AF Olshan, NN Hayes. International Journal of Radiation Oncology Biology Physics 2016 Mar; 94 (4), 864
    16. Molecular Profile of Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma Stratified by Smoking Status. JP Zevallos, E Yim, P Brennan, AY Liu, JM Taylor, M Weissler, D Anantharaman, B Abedi-Ardekani, AF Olshan, NN Hayes. International Journal of Radiation Oncology Biology Physics 2016, 94 (4), 864
    17. A rare truncating BRCA2 variant and genetic susceptibility to upper aerodigestive tract cancer. Delahaye-Sourdeix M, Anantharaman D, Timofeeva MN, Gaborieau V, Chabrier A, Vallée MP, Lagiou P, Holcátová I, Richiardi L, Kjaerheim K, Agudo A, Castellsagué X, Macfarlane T V, Barzan L, Canova C, Thakker N S, Conway DI, Znaor A, Healy CM, Ahrens W, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Fabianova E, Nicolae I, Bencko V, Foretova L, Janout V, Paula M, Koifman S, Menezes A, Wünsch-Filho V, Eluf-Neto J, Boffetta P, Fernández L, Polesel J, Lener M, Jaworowska E, Lubiski J, Boccia S, Rajkumar T, Samant TA, Mahimkar MB, Franceschi S, Byrnes G, Brennan P, McKay JD*. Journal of National Cancer Institute. 2015 107(5): djv037. PMID: 25838448
    18. The 12p13.33/RAD52 locus and genetic susceptibility to squamous cell cancers of upper aerodigestive tract. Delahaye-Sourdeix M, Oliver J, Maria MN, Gaborieau V, Johansson M, Chabrier A, Magdalena MB, Brenner D, Maxime MP, Anantharaman D, Lagiou P, Holcátová I, Richiardi L, Kjaerheim K, Agudo A, Castellsagué X, Tatiana TV, Barzan L, Canova C, Nalin NS, David DI, Znaor A, Claire CM, Ahrens W, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Fabianova E, Nicolae I, Bencko V, Foretova L, Janout V, Paula M, Koifman S, Menezes A, Wünsch-Filho V, Eluf-Neto J, Boffetta P, Fernández L, Serraino D, Lener M, Jaworowska E, Lubinski J, Boccia S, Rajkumar T, Tanuja TA, Manoj MB, Matsuo K, Franceschi S, Byrnes G, Brennan P, James JD*. PLoS One. 2015;10(3):e0117639. PMID: 25793373
    19. Circulating tumor DNA as a 'liquid biopsy' in head and neck cancer. S Perdomo, D Anantharaman, J Mckay, P Brennan. Cancer Research 2015; 75 (15 Supplement), 5230-5230
    20. Human Papillomavirus 16 E6 Antibodies in Individuals Without Diagnosed Cancer: A Pooled Analysis. Lang Kuhs KA, Anantharaman D, Waterboer T, Johansson M, Brennan P, Michel A, Willhauck-Fleckenstein M, Purdue MP, Holcátová I, Ahrens W, Lagiou P, Polesel J, Simonato L, Merletti F, Healy CM, Kjaerheim K, Conway DI, Macfarlane TV, Thomson P, Castellsagué X, Znaor A, Black A, Huang W, Krogh V, Trichopoulou A, Bueno-de-Mesquita HB, Clavel-Chapelon F, Weiderpass E, Ekströ m J, Riboli E, Tjønneland A, Sánchez M, Travis RC, Hildesheim A, Pawlita M, Kreimer A R*. Cancer Epidemiology, Biomarkers & Prevention, 2015. PMID: 25623733 (*Joint first author publication)
    21. No causal role for human papillomavirus infections in lung cancer. Anantharaman D, Gheit T, Waterboer T, Halec G, Carreira C, Abedi-Ardekani B, McKay-Chopin S, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Mates D, Janout V, Foretova L, Bencko V, Rudnai P, Fabianova E, Tjønneland A, Travis RC, Boeing H, Quirós JR, Johansson M, Krogh V, Bueno-de-Mesquita HB, Kotanidou A, Clavel-Chapelon F, Weiderpass E, Johansson M, Pawlita M, Scelo G, Tommasino M, Brennan P*. Cancer Research. 2014 Jul 1;74(13):3525-34. PMID: 24760422
    22. Genetic and epidemiology characterization of head and neck cancers by targeted sequencing. S Perdomo, L Reis, D Anantharaman, J Mckay, P Brennan. Cancer Research 2014; 74 (19 Supplement), 4144-4144
    23. Genetic variants in nicotine addiction and alcohol metabolism genes, oral cancer risk and the propensity to smoke and drink alcohol: a replication study in India. Anantharaman D, Chabrier A, Gaborieau V, Franceschi S, Herrero R, Rajkumar T, Samant T, Mahimkar M, Brennan P, McKay JD*. PLoS One. 2014 Feb 5;9(2):e88240. PMID: 24505444
    24. Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE Study.Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, Gaborieau V, Marron M, Lagiou P, Ahrens W, Holcátová I, Merletti F, Kjaerheim K, Talamini R, Simonato L, Castellsague X, Macfarlane TV, Biggs AM, Thakker N, Znaor A, Thomson P, Canova C, Conway DI, Healy CM, Tommasino M, Pawlita M, Brennan P*. Journal of Nationall Cancer Institute. 2013 Apr 17;105(8):536-45. PMID: 23503618
    25. An analysis of human papilloma virus (HPV) E6 antibodies and risk of head and neck cancer: two large European studies. P Brennan, M Johannson, D Anantharaman, M Pawlita, AKreimer. Cancer Research 2013; 73 (8 Supplement), 3625-3625
    26. Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mahimkar MB*, Samant TA, Kannan S, Tulsulkar J, Pai PS, Anantharaman D. Molecular Carcinogenesis. 2012, Volume 51 (S1): E94–E103. PMID: 22213390
    27. Polymorphisms in tobacco metabolism and DNA repair genes modulate oral precancer and cancer risk. Anantharaman D, Samant TA, Sen S, Mahimkar MB. Oral Oncology. 2011 Sep;47(9):866-72. PMID: 21741876
    28. Human papillomavirus serology and the risk of lung cancer. D Anantharaman, M Pawlita, T Waterboer, D Zaridze, A Mukeria, D Mates, N Szeszenia-Dabrowska, P Rudnai, J Lissowska, V Bencko, G Scelo, P Boffetta, P Brennan. Cancer Research 2011, 71 (8 Supplement), 1890-1890
    29. Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer. Anantharaman D, Marron M, Lagiou P, Samoli E, Ahrens W, Pohlabeln H, Slamova A, Schejbalova M, Merletti F, Richiardi L, Kjaerheim K, Castellsague X, Agudo A, Talamini R, Barzan L, Macfarlane TV, Tickle M, Simonato L, Canova C, Conway DI, McKinney PA, Thomson P, Znaor A, Healy CM, McCartan BE, Hashibe M, Brennan P, Macfarlane GJ. Oral Oncology. 2011 Aug;47(8):725-31. PMID: 21684805
    30. Sequence Variants and the Risk of Head and Neck Cancer: Pooled Analysis in the INHANCE Consortium. Chuang SC, Agudo A, Ahrens W, Anantharaman D, Benhamou S, Boccia S, Chen C, Conway DI, Fabianova E, Hayes RB, Healy CM, Holcatova I, Kjaerheim K, Lagiou P, Lazarus P, Macfarlane TV, Mahimkar MB, Mates D, Matsuo K, Merletti F, Metspalu A, Morgenstern H, Muscat J, Cadoni G, Olshan AF, Purdue M, Ramroth H, Rudnai P, Schwartz SM, Simonato L, Smith EM, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Thomson P, Wei Q, Zaridze D, Zhang ZF, Znaor A, Brennan P, Boffetta P, Hashibe M*. Frontiers in Oncology. 2011; Volume 1 (13): 1-15. PMID: 22655231
    31. Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Varela-Lema L, Taioli E, Ruano-Ravina A, Barros-Dios JM, Anantharaman D, Benhamou S, Boccia S, Bhisey RA, Cadoni G, Capoluongo E, Chen CJ, Foulkes W, Goloni-Bertollo EM, Hatagima A, Hayes RB, Katoh T, Koifman S, Lazarus P, Manni JJ, Mahimkar M, Morita S, Park J, Park KK, Pavarino Bertelli EC, de Souza Fonseca Ribeiro EM, Roy B, Spitz MR, Strange RC, Wei Q, Ragin CC. Genetics in Medicine. 2008 Jun;10(6):369-84. PMID: 18496222
    32. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Anantharaman D, Chaubal PM, Kannan S, Bhisey RA, Mahimkar MB*. Carcinogenesis. 2007 Jul;28(7):1455-62. PMID: 17307803
  • Team


    Priya R Prabhu, PhD Student

    The HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC) has participants who have received one, two and three vaccine doses with varying window periods in between the doses and collection of their plasma samples at defined time points after vaccination. My study looks at intermediate endpoints of the trial namely the sero-conversion status and its correlation with vaccine doses received.

    priya-r-prabhu
    priya-r-prabhu

    Priya R Prabhu, PhD Student

    The HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC) has participants who have received one, two and three vaccine doses with varying window periods in between the doses and collection of their plasma samples at defined time points after vaccination. My study looks at intermediate endpoints of the trial namely the sero-conversion status and its correlation with vaccine doses received.

    SubhaSankaran, Data Manager

    I look after database management of the central human sample storage facility of the HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC). My work includes storage, appropriate retrieval and data management of the samples received from all collaborating centers in India.

    Subha
    Subha

    SubhaSankaran, Data Manager

    I look after database management of the central human sample storage facility of the HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC). My work includes storage, appropriate retrieval and data management of the samples received from all collaborating centers in India.

    Rintu Varghese, Technical Assistant

    I provide technical assistance for the project on the HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC). In addition I also operate and perform analysis for RGCB's transmission electron microscope including imaging, sample preparation, operation and maintenance.

    Rintu-Varghese
    Rintu-Varghese

    Rintu Varghese, Technical Assistant

    I provide technical assistance for the project on the HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC). In addition I also operate and perform analysis for RGCB's transmission electron microscope including imaging, sample preparation, operation and maintenance.

    T. R. Kannan, Technical Assistant

    I provide technical assistance for the serology and genotyping assays as a part of the project on the HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC).

    Kannan
    Kannan

    T. R. Kannan, Technical Assistant

    I provide technical assistance for the serology and genotyping assays as a part of the project on the HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC).

    Jinu Austin, Laboratory Assistant

    My work includes maintenance and retrieval of patient's samples in the HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC) as well as other laboratory support required for the experiments.

    Jinu-Austin
    Jinu-Austin

    Jinu Austin, Laboratory Assistant

    My work includes maintenance and retrieval of patient's samples in the HPV 2 dose Vs 3 dose vaccination trial with the prophylactic vaccine GardasilTM, funded by the Bill & Melinda Gates Foundation through the International Agency for Research on Cancer (IARC) as well as other laboratory support required for the experiments.

    Edwin S, Senior Technical Assistant

    I look after general laboratory management and coordination of the laboratories with the RGCB central stores, RGCB purchase and RGCB administration. I am also involved in the management of the RGCB cafeteria and catering services.

    Edwin
    Edwin

    Edwin S, Senior Technical Assistant

    I look after general laboratory management and coordination of the laboratories with the RGCB central stores, RGCB purchase and RGCB administration. I am also involved in the management of the RGCB cafeteria and catering services.

    Vivek Ashok Kumar, Project Assistant

    I am interested in gene editing as a treatment for HPV induced cervical cancer. My project is an extension of the previous work done in the lab where it was demonstrated that disrupting the E7 gene with TALENs in the HPV16 cervical cancer cell line (SiHa) leads to necrosis. My work is focused on looking into this process in an in vivo model and the possibility that necrosis elicits an immune response against the cancer cells. I also expect to test the gene editing potential of CRISPR as a mode of treatment.

    Vivek Ashok Kumar
    Vivek Ashok Kumar

    Vivek Ashok Kumar, Project Assistant

    I am interested in gene editing as a treatment for HPV induced cervical cancer. My project is an extension of the previous work done in the lab where it was demonstrated that disrupting the E7 gene with TALENs in the HPV16 cervical cancer cell line (SiHa) leads to necrosis. My work is focused on looking into this process in an in vivo model and the possibility that necrosis elicits an immune response against the cancer cells. I also expect to test the gene editing potential of CRISPR as a mode of treatment.

    Aparna. G. J, PhD student

    My research work focuses on cancers arising at the oral cavity, pharynx and larynx, grouped together as head and neck cancers and examining the prevalence of different HPV genotypes in them in order to gain a better understanding of the epidemiology of the HPV-driven head and neck cancers. Additionally, I am also involved in designing an sensitive and specific system to detect multiple HPV types in human samples.

    Aparna. G. J
    Aparna. G. J
  • Alumni